Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center

Guiyang, China

Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center

Guiyang, China
SEARCH FILTERS
Time filter
Source Type

Lin X.,Guizhou University | Lin X.,North Sichuan Medical College | Zou X.,North Sichuan Medical College | Wang Z.,Guiyang Medical University | And 19 more authors.
Oncotarget | Year: 2016

The correlation between Heme oxygenase-1 (HO-1) and dominant-negative Ikaros isoform 6 (IK6) is unclear. Firstly, we detected that IK6 existed in 20 of 42 (47.6%) adult BCR-ABL1-positive B-lineage acute lymphoblastic leukemia (BCR-ABL1- positive B-ALL) by using reverse transcribed polymerase chain reaction (PCR) and nucleotide sequencing. IK6-positive patients had an unfavorable outcome compared with IK6-negative ones. Further study showed that the level of HO-1 expression was higher in IK6-positive patients' samples than that in IK6-negative ones. And there was a strong correlation between the expression of IK6 and HO-1. The growth of primary CD34+ leukemic cells derived from our IK6-positive patients' pool was prohibited by silencing HO-1, further promoting their apoptosis. Furthermore, primary CD34+ leukemic cells derived from IK6-positive patients shown poor responses to imatinib in comparison with wild-type (IK1) patients, suggesting that the expression of IK6 resisted to imatinib in adult BCR-ABL1-positive B-ALL. Importantly, inhibition of HO-1 also increased their sensitivity to tyrosine kinase inhibitors (TKIs). Finally, we found that IK6 activated downstream STAT5, and HO-1 was one of the downstream target genes of STAT5. In conclusion, HO-1 is an essential survival factor in BCR-ABL1- positive B-ALL with IK6, and targeting HO-1 can attenuate the negative impact of IK6.


Huang J.,Guiyang Medical University | Huang J.,Guizhou University | Huang J.,Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center | Guo P.,Peoples Hospital of Guizhou Province | And 9 more authors.
International Journal of Oncology | Year: 2016

There is an urgent requirement for a new therapeutic target for activated B-cell-like lymphoma (ABC-DLBCL), which is known to have dismal outcome and constitutive activation of NF-B. Heme oxygenase-1 (HO-1) can inhibit apoptosis and promote proliferation in many cancers. To our knowledge, no studies have been performed on the correlation between HO-1 and DLBCL. In this study, immunohistochemical analysis of 31 tumor tissues from DLBCL patients [20 of ABC subtype and 11 of germinal center B-cell-like (GCB) subtype] and 11 normal lymph nodes revealed that HO-1 overexpression was characteristic of ABC-DLBCL. In addition, HO-1 mRNA expression levels were consistent with the immunohistochemistry results. High levels of HO-1 expression were significantly correlated with the involvement of more than 1 extranodal site (p=0.025), with a high positivity rate of Ki-67 (p<0.01). Similar to its anti-apoptotic role in other malignancies, HO-1 upregulation suppressed apoptosis of the ABC-DLBCL cell line OCI-ly10, whereas its downregulation sensitized the tumor cells to chemotherapeutic drugs. Further study demonstrated that the HO-1 overexpression was mediated by constitutively activated NF-B which together played an anti-apoptotic role in ABC-DLBCL. Combination of the NF-B inhibitor Bay11-7082 and the lentivirus vector Lenti-siHO-1 significantly decreased HO-1 protein expression and increased apoptosis in OCI-ly10 cells. However, in GCB-DLBCL cells with low levels of NF-B expression, the TNF-mediated activation of NF-B leading to HO-1 upregulation rescued the cells from apoptosis caused by HO-1 silencing. These results indicated that HO-1 can be a potential target for the treatment of ABC-DLBCL.


Lin X.,Guiyang Medical College | Lin X.,The Affiliated Hospital of Guiyang Medical College | Lin X.,Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center | Fang Q.,The Affiliated Baiyun Hospital of Guiyang Medical College | And 19 more authors.
Leukemia Research | Year: 2015

There are few studies on the correlation between heme oxygenase-1 (HO-1) and acute myeloid leukemia (AML). We found that HO-1 was aberrantly overexpressed in the majority of AML patients, especially in patients with acute monocytic leukemia (M5) and leukocytosis, and inhibited the apoptosis of HL-60 and U937 cells. Moreover, silencing HO-1 prolonged the survival of xenograft mouse models. Further studies demonstrated that HO-1 suppressed the apoptosis of AML cells through activating the JNK/c-JUN signaling pathway. These data indicate a molecular role of HO-1 in inhibiting cell apoptosis, allowing it to be a potential target for treating AML. © 2015 Elsevier Ltd.

Loading Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center collaborators
Loading Guizhou Provincial Laboratory of Hematopoietic Stem Cell Transplantation Center collaborators